What Evolus (EOLS) Said on Its Q3 Earnings Call
Evolus (EOLS) cut its full-year non-GAAP operating expense guidance to $210M-$213M and reaffirmed 2028 revenue targets of $450M-$500M with adjusted EBITDA margins of 13%-15%. The company expects FDA approval for Sculpt in Q4 2026 and a 2027 launch. Evolysse and Estyme gel lines are projected to contribute 10%-12% of full-year revenue. Evolus added over 500 purchasing accounts, bringing its total to over 19,000.
How this was made
The 30-second read
Why it matters
The guidance reduction signals higher operating costs than previously expected, which may pressure the share price until pipeline milestones are achieved.
Market read
Evolus' updated expense guidance is the primary new information, affecting valuation and potentially influencing peer sentiment in the aesthetic‑device sector.
What to watch
Potential upside from upcoming FDA approvals for Sculpt and Profhilo could mitigate expense concerns.
Background
Evolus is a commercial‑stage medical aesthetics company best known for its Jeuveau botulinum toxin product.
Ticker impact
Evolus reduced its full-year non-GAAP operating expense guidance to $210M-$213M and reaffirmed 2028 revenue and EBITDA targets.
likely downside as investors price in higher expense outlook
The expense guidance reduction is a fresh, material update from the Q3 earnings call, directly affecting valuation assumptions.
Market effects
May prompt re‑rating of other aesthetic‑device makers as cost pressures become a focus.
Limited to U.S. biotech/aesthetic sector.
Low; impact confined to niche medical‑aesthetics space.
Counterpoint
If the expense cut is offset by strong product pipeline progress, the stock could rebound.
Key entities
- CompanyEvolus, Inc.
Medical aesthetics firm reporting Q3 earnings call.
- ExecutiveRui Avelar
Chief Medical Officer and Head of R&D providing product timeline updates.